Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

First Quarter Highlights Total revenues increased to $88.4 billion, up 3.7% compared to prior year GAAP diluted EPS of $0.88 and Adjusted EPS of $1.31 Generated cash flow from operations of $4.9 billion 2024 Full-Year Guidance Revised GAAP diluted EPS guidance to at least $5.64 from at least $7.06 Revised Adjusted EPS guidance to at least $7.00 from at least $8.30 Revised cash flow from operations guidance to at least $10.5 billion from at least $12.0 billion CEO Commentary "The current environment does not diminish our opportunities, enthusiasm, or the long-term earnings power of our company. We are confident we have a pathway to address our near-term Medicare Advantage challenges.

CVS HEALTH CORPORATION REPORTS FIRST QUARTER 2024 RESULTS AND REVISES FULL-YEAR 2024 GUIDANCE

CVS Health reported first quarter profits were cut almost in half to $1.1 billion compared to the year-ago period thanks to higher costs to treat patients insured by Medicare plans the company sells.

CVS Health Profits Tumble To $1.1 Billion On Higher Costs To Treat Seniors

After underperforming its peers in the healthcare sector, shares of CVS Health Co. NYSE: CVS are now nearing a 52-week low price. Underperforming the Health Care Select Sector SPDR Fund NYSEARCA: XLV by as much as 14% over the past year, CVS stock is now dangerously close to its $64.4 a share low.

CVS Stock is Nearing a 52-Week Low, Better Buy Than Walgreens?

Coca-Cola

Procter & Gamble

The U.S. economy is in a precarious situation at the moment — an unusual balance between rampant inflation and investor confidence. However, to cool down inflation, policymakers are hinting at not lowering interest rates.

Preparing for the Worst: 3 Resilient Stocks to Buy Before the Next Market Crash

CVS Health (NYSE: CVS) will report its Q1 2024 results on Wednesday, May 1. We expect the company's revenues to come in at $90 billion, slightly above the consensus estimate of $89.2 billion.

Higher Medical Costs Likely Weighed On CVS Health's Q1 Earnings

General Motors

Sibanye Stillwater

Outside of recent rumblings, the sentiment surge in the equities space this year has taken some of the shine off value stocks to buy on the dip. It's not that the concept lost relevance or popularity.

3 Value Stocks to Buy on the Dip: April 2024

CVS is getting into the business of making copycat biologic drugs, known as biosimilars, to profit directly from blockbusters going generic.

Coming to a CVS Near You: A Store Brand Monoclonal Antibody

CVS Health is facing multiple issues, including lower coronavirus-related revenue. However, the company still has a business that seems built to last.

Is This Beaten-Down Dividend Stock a Buy?

CVS Health (CVS) closed at $67.18 in the latest trading session, marking a -0.22% move from the prior day.

CVS Health (CVS) Stock Drops Despite Market Gains: Important Facts to Note

Staff at CVS Health's unit Omnicare in Las Vegas voted to join the Pharmacy Guild, becoming the first location at the national pharmacy chain to join the union.

CVS Omnicare staff in Las Vegas vote to join new union

Nearly 30 pharmacy staff at the Las Vegas branch of CVS's Omnicare will now join The Pharmacy Guild, which will represent them in labor negotiations with CVS.

A CVS pharmacy in Vegas becomes first to join new national pharmacy union

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for CVS Health (CVS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.

Gear Up for CVS Health (CVS) Q1 Earnings: Wall Street Estimates for Key Metrics

Americold Realty

Home Depot

Prologis

XP Investimentos

Amid global tensions and some severe market pullbacks, investors might seek refuge in defensive sectors, particularly oversold stocks offering high dividends. With uncertainties looming over geopolitical conflicts and dwindling prospects of the Federal Reserve's rate cuts, it might be wise to turn attention toward resilient stocks poised for potential upside, especially if you're a conservative, long-term, value-orientated investor.

5 High-Yielding Oversold Stocks with Bullish Ratings

The latest trading day saw CVS Health (CVS) settling at $67.33, representing a -0.65% change from its previous close.

Why CVS Health (CVS) Dipped More Than Broader Market Today

Staff specialists to provide comprehensive skills training and job placement, as well as wraparound health care services  BATON ROUGE, La. , April 25, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced the opening of a new workforce development and community resource center designed to help the Baton Rouge community overcome employment barriers and increase access to local health care services.

CVS Health opens new workforce development and community resource center in Baton Rouge

Hershey

Johnson & Johnson

Lowe's

McDonald's

UnitedHealth Group

Visa

Recent market volatility may have many market participants buying major tech stocks on the dip, but the genuine opportunity may lie with blue chip stocks to buy on the dip. Blue-chips can be a great cornerstone for your portfolio.

7 blue chip stocks to Buy on the Dip: April 2024

CVS Health (CVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: CVS Health (CVS) Q1 Earnings Expected to Decline

The investment builds upon efforts to increase access to permanent supportive housing, reduce homelessness WOONSOCKET, R.I. , April 24, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced it has invested $19.2 million through Boston Financial to build 85 new affordable housing units in Arvada, Colorado.

CVS Health invests $19.2 million in affordable housing in Arvada, Colorado

Amgen

Cigna

Sanofi

The Federal Trade Commission is working to accelerate its inquiry into the prescription-drug middlemen known as pharmacy-benefit managers, while also expanding its scrutiny of drug patents that can keep prescription prices artificially high, FTC Chair Lina Khan told reporters Tuesday.

FTC looking to accelerate inquiry into prescription-drug middlemen, chair says

CVS Health has been underperforming due to changes in the Medicare Advantage program. Despite the impact on profits in the near term, CVS' long-term growth prospects remain intact. The stock is currently undervalued with a low P/E ratio.

CVS Health: 8x P/E, 8% Growth Projection - It's A Market Blind Spot

LOS ANGELES--(BUSINESS WIRE)--Jason Wu Beauty brings a curated collection of products to 3,000+ CVS stories across the United States.

Jason Wu Beauty Brings a Curated Collection of Products to 3,000+ CVS Stores Across the United States

Ally Financial

FedEx

Realty Income Corp

Starbucks

Walmart

Wynn Resorts

Realty Income's stock price is down, but it has a resilient business model that continues to perform well despite the high-interest-rate environment. Starbucks is reinventing itself and still has massive growth plans.

The Smartest Dividend Stocks to Buy With $400 Right Now

CVS Health (CVS) closed at $69.39 in the latest trading session, marking a +1.15% move from the prior day.

CVS Health (CVS) Rises As Market Takes a Dip: Key Facts

General Mills

Invesco S&P 500 High Dividend Low Volatility ETF

As the earnings season gets underway on Wall Street, the euphoria of rapid gains is starting to wane. Economic uncertainties, geopolitical tensions and the ever-present threat of inflation have left investors feeling like they're navigating a constant financial storm.

3 Defensive Stocks to Buy for Increased Volatility in April

CVS Health Corporation is set to report its Q1 earnings on May 1st with analysts expecting revenue of $89 billion and EPS of $1.70. The CVS Health share price has underperformed the S&P 500 Index by almost 20% YTD, presenting a buying opportunity due to its discounted valuation and potential for upside. The recent decline in CVS stock can be attributed to fears of lower-than-expected payment increases for Medicare Advantage Plans, but the decline may now be priced in.

News for CVS Health Stock (CVS)